SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentatio ...

Core Insights - CytomX Therapeutics has appointed Rachael Lester as Senior Vice President and Chief Business Officer to enhance its strategic long-term value creation and partnering strategy [1][2] - The company is well-positioned to advance its clinical assets, particularly CX-2051 and CX-801, which target high unmet medical needs in cancer treatment [2][4] Company Overview - CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked biologics aimed at localized tumor treatment [4] - The company's PROBODY therapeutic platform enables the creation of safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates, T-cell engagers, and immune modulators [4] Leadership Experience - Rachael Lester brings over 20 years of experience in corporate strategy and business development within the biopharmaceutical industry [3] - Prior to joining CytomX, she held significant roles at Replicate Bioscience and Harpoon Therapeutics, where she was instrumental in securing financing and establishing major partnerships [3] Clinical Pipeline - CytomX's lead clinical assets include CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine, both of which have broad potential across various cancer types [4] - CX-2051 is designed to treat multiple EpCAM-expressing epithelial cancers, including colorectal cancer, while CX-801 has applications in both immuno-oncology sensitive and insensitive tumors [4] Strategic Collaborations - The company has established strategic partnerships with leading oncology firms such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna to enhance its research and development efforts [4]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localized tumor treatment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM), and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] Upcoming Events - CytomX management will participate in several investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 4, 2025, with a fireside chat at 8:35 a.m. ET [2] - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, with a formal presentation at 11:30 a.m. ET [2] - Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, with a fireside chat at 1:05 p.m. ET [2] - A live webcast of the presentations will be available on CytomX's website, and management will be available for one-on-one meetings with registered investors [2]

Group 1 - CytomX Therapeutics, Inc. will report its second quarter financial results on August 7, 2025, after U.S. market close [1] - A conference call and webcast will follow the financial results announcement at 5:00 p.m. ET / 2:00 p.m. PT [1][2] - Participants can access the live webcast from CytomX's website and are advised to register at least 10 minutes prior to the call [2] Group 2 - CytomX is a clinical-stage biopharmaceutical company focused on developing conditionally activated biologics for cancer treatment [3] - The company's pipeline includes therapeutic candidates such as CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CytomX has established collaborations with major oncology leaders including Amgen, Astellas, and Bristol Myers Squibb [3]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localized tumor treatment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies [3] - CytomX's pipeline includes therapeutic candidates such as CX-2051 and CX-801, targeting various cancer types [3] Pipeline Details - CX-2051 is a masked, conditionally activated antibody-drug conjugate (ADC) targeting epithelial cell adhesion molecule (EpCAM), with potential applications in multiple EpCAM-expressing epithelial cancers, including colorectal cancer (CRC) [3] - CX-801 is a masked interferon alpha-2b PROBODY cytokine, applicable in both immuno-oncology sensitive and insensitive tumors [3] - The company has established strategic collaborations with major oncology leaders including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Sean McCarthy, CEO and Chairman of CytomX, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 2:35 p.m. ET [1] - A live webcast of the presentation will be available on CytomX's website, and management will hold one-on-one meetings with registered investors at the conference [2]